Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

Horby P., Staplin N., Haynes R., Landray M.

DOI

10.1016/S0140-6736(21)01422-7

Type

Working paper

Publication Date

24/07/2021

Volume

398

Keywords

Antibodies, Monoclonal, Humanized, COVID-19, Humans, SARS-CoV-2

Permalink Original publication